Association between Medication Possession Ratio (MPR) in Type 2 Diabetes Mellitus Patients and Glycosylated Haemoglobin (HbA1c) in Klinik Kesihatan Tendong, Kelantan: A Preliminary Study
Keywords:
MPR, MRCI, Age, HbA1c outcomes, diabetes mellitusAbstract
Background: Diabetes mellitus is highly prevalent in Malaysia, affecting a sizeable portion of the population. The country faces a growing burden, with an estimated prevalence rate of around 18.3%. Several factors contribute to the non-adherence of diabetes medication including demographic factors, complex medication regimens, inadequate communication with healthcare providers and cultural beliefs. Identifying the major factor that led to non-adherence on medication should be prioritized to achieve good glycaemic control with a HbA1c target of less than 7% for most diabetic patients. Objectives: This study aims to identify the factors affecting patients’ Medication Possession Ratio (MPR) and how MPR is associated with HbA1c outcomes from retrospective data collection. Method: A retrospective study was conducted on a selected sample of 300 individuals who attended Klinik Kesihatan Tendong from May to June 2023. Secondary data on MPR was extracted from the Pharmacy Information System (PhIS) while HbA1c outcomes were obtained from the National Diabetes Registry database. Results: The study successfully demonstrated significant association between MPR with HbA1c outcomes in the patients. Patients with good adherence accounted for the majority of the study population (N=80.5%) with HbA1c levels below 7. Conclusion: The use of MPR as a tool to determine medication adherence of patients was proven to have significant association with HbA1c outcomes.References
[1] Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: An overview. Avicenna J Med. 2020 Oct;10(04):174–88.
[2] International Diabetes Federation. 10th edition [Internet] 2021. [updated 2021; Cited 2023 June 6]; Available from: http://www.diabetesatlas.org
[3] Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract. 2014;103(2):150–60.
[4] Brown MT, Bussell JK. Medication adherence: WHO cares? Vol. 86, Mayo Clinic Proceedings. Elsevier Ltd; 2011. p. 304–14.
[5] Dehdari L, Dehdari T. The determinants of anti-diabetic medication adherence based on the experiences of patients with type 2 diabetes. Archives of Public Health. 2019 May 16;77(1).
[6] Vermeire E, Hearnshaw H, van Royen P, Denekens J. Patient adherence to treatment: Three decades of research. A comprehensive review. Vol. 26, Journal of Clinical Pharmacy and Therapeutics. 2001. p. 331–42.
[7] Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Vol. 15, Pharmacoepidemiology and Drug Safety. 2006. p. 565–74.
[8] Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Annals of Pharmacotherapy. 2009 Jan;43(1):36–44.
[9] Soraya IA, Sauriasari R, Prawiroharjo P, Risni HW. ARTICLE HISTORY The Association between Adherence to Oral Antihyperglycemic Agent and HbA1c Level. Vol. 9, Pharmaceutical Sciences and Research.
[10] Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007 Nov;50(11):2239–44.
[11] Rydén L, Standl E, Małgorzata B, van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Vol. 28, European Heart Journal. Oxford University Press; 2007. p. 88–136.
[12] Mustaming A, Ying Ying C, Kanthavelu C, Chong Gar Mit E, Abu Bakar F, Azahadi Omar M, et al. Elderly Health Volume I: Methodology and General Findings. National Health and Morbidity Survey. 2018.
[13] Kämpfen F, Wijemunige N, Evangelista B. Aging, non-communicable diseases, and old-age disability in low- and middle-income countries: a challenge for global health. Vol. 63, International Journal of Public Health. Springer International Publishing; 2018. p. 1011–2.
[14] Walsh CA, Cahir C, Bennett KE. Longitudinal Medication Adherence in Older Adults with Multimorbidity and Association with Health Care Utilization: Results from the Irish Longitudinal Study on Ageing. Annals of Pharmacotherapy. 2021 Jan 1;55(1):5–14.
[15] Kim SJ, Kwon OD, Han EB, Lee CM, Oh SW, Joh HK, et al. Impact of number of medications and age on adherence to antihypertensive medications: A nationwide population-based study. Medicine (United States). 2019 Dec 1;98(49).
[16] de Vries ST, Keers JC, Visser R, de Zeeuw D, Haaijer-Ruskamp FM, Voorham J, et al. Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. J Psychosom Res. 2014 Feb;76(2):134–8.
[17] Park HY, Seo SA, Yoo H, Lee K. Medication adherence and beliefs about medication in elderly patients living alone with chronic diseases. Patient Prefer Adherence. 2018; 12:175–81.
[18] Ghimire S, Peterson GM, Castelino RL, Jose MD, Zaidi STR. Medication Regimen Complexity and Adherence in Haemodialysis Patients: An Exploratory Study. Am J Nephrol. 2016 Jun 8;43(5):318–24.
[19] Advinha AM, de Oliveira-Martins S, Mateus V, Pajote SG, Lopes MJ. Medication regimen complexity in institutionalized elderly people in an aging society. Int J Clin Pharm. 2014;36(4):750–6.
[20] Ayele AA, Tegegn HG, Ayele TA, Ayalew MB. Medication regimen complexity and its impact on medication adherence and glycaemic control among patients with type 2 diabetes mellitus in an Ethiopian general hospital. BMJ Open Diabetes Res Care. 2019 Jun 1;7(1).
[21] Fröhlich SE, Zaccolo A v., da Silva SLC, Mengue SS. Association between drug prescribing and quality of life in primary care. Pharmacy World and Science. 2010 Dec;32(6):744–51.
[22] George J, Phun YT, Bailey MJ, Kong DCM, Stewart K. Development validation of the medication regimen complexity index. Annals of Pharmacotherapy. 2004 Sep;38(9):1369–76.
[23] Chin SS, Lau SW, Lim PL, Wong CM, Ujang N. Medication adherence, its associated factors and implication on glycaemic control in patients with type 2 diabetes mellitus: A cross-sectional study in a Malaysian primary care clinic. Malaysian Family Physician [Internet]. 2023 Mar 14; 18:14. Available from: https://e-mfp.org/wp-content/uploads/18.14R1OAMedicationAdherence.pdf
[24] Anwar Hammad M, Azhar Syed Sulaiman S. THE EFFECT OF PATIENT’S ADHERENCE ON HBA1C CONTROL: The use of metformin with its contraindications among Diabetics type 1 and 2 patients in Penang general hospital View project Probability of Dying and Survival Analysis of Diabetic and /Hypertensive Patients Who Undergone Haemodialysis with Heart Disease Complication: A Comparison Between a Haemodialysis Center Jakarta, Indonesia and Penang, Malaysia View project [Internet]. 2017. Available from: https://www.researchgate.net/publication/318909992
[25] Rhee MK, Slocum W, Ziemer DC, Culler SD, Cook CB, El-Kebbi IM, et al. Patient adherence improves glycaemic control. Diabetes Educator. 2005 Mar;31(2):240–50.
[26] Boye Vivian T Thieu Maureen J Lage Heather Miller Rosirene Paczkowski KS. The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study. [cited 2023 May 30]; Available from: https://doi.org/10.1007/s12325-022-02106-4
[27] Azmi NL, Md Rosly NA, Tang HC, Che Darof AF, Zuki ND. Assessment of medication adherence and quality of life among patients with type 2 diabetes mellitus in a tertiary hospital in Kelantan, Malaysia. Journal of Pharmacy. 2021 Jul 31;1(2):79–86.
[28] Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017 Jun 1;5(6):431–7.
[29] Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Intensive glycaemic control for patients with type 2 diabetes: Systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ (Online). 2011 Dec 3;343(7834):1136.
[30] Boye KS, Thieu VT, Lage MJ, Miller H, Paczkowski R. The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study. Adv Ther. 2022 May 1;39(5):2208–21.
[31] Kennedy-Martin T, Boye KS, Peng X. Cost of medication adherence and persistence in type 2 diabetes mellitus: A literature review. Vol. 11, Patient Preference and Adherence. Dove Medical Press Ltd.; 2017. p. 1103–17.
[32] Kleinman NL, Schaneman JL, Lynch WD. The association of insulin medication possession ratio, use of insulin glargine, and health benefit costs in employees and spouses with type 2 diabetes. In: Journal of Occupational and Environmental Medicine. Lippincott Williams and Wilkins; 2008. p. 1386–93.
[33] Teng CL, Chan CW, Wong PS. Medication Adherence of Persons with Type 2 Diabetes in Malaysia: A Scoping Review and Meta-Analysis. Vol. 37, Journal of the ASEAN Federation of Endocrine Societies. ASEAN Federation of Endocrine Societies; 2022. p. 75–82.
[34] Jaam M, Awaisu A, Ibrahim MI, Kheir N. Synthesizing and Appraising the Quality of the Evidence on Factors Associated with Medication Adherence in Diabetes: A Systematic Review of Systematic Reviews. Value Health Reg Issues. 2017 Sep 1; 13:82–91.
[35] Yung CH. An internal audit of diabetes care for type 2 diabetic patients in a public hospital diabetes clinic in Malaysia. Malaysian Journal of Medical Sciences. 2017;24(2):55–60.
[36] Blackburn DF, Swidrovich J, Lemstra M. Non-adherence in type 2 diabetes: Practical considerations for interpreting the literature. Vol. 7, Patient Preference and Adherence. 2013. p. 183–9.
[37] Smaje A, Weston-Clark M, Raj R, Orlu M, Davis D, Rawle M. Factors associated with medication adherence in older patients: A systematic review. Aging Medicine. 2018 Dec 1;1(3):254–66.
[38] Kirkman MS, Rowan-Martin MT, Levin R, Fonseca VA, Schmittdiel JA, Herman WH, et al. Determinants of adherence to diabetes medications: Findings from a large pharmacy claims database. Diabetes Care. 2015 Apr 1;38(4):604–9.
[39] Chudiak A, Uchmanowicz I, Mazur G. Relation between cognitive impairment and treatment adherence in elderly hypertensive patients. Clin Interv Aging. 2018; 13:1409–18.
[40] Johnell K. Inappropriate Drug Use in People with Cognitive Impairment and Dementia: A Systematic Review. Vol. 10, Current Clinical Pharmacology. 2015.
[41] Brundisini F, Vanstone M, Hulan D, DeJean D, Giacomini M. Type 2 diabetes patients’ and providers’ differing perspectives on medication nonadherence: A qualitative meta-synthesis. BMC Health Serv Res. 2015 Nov 23;15(1).
[42] Ahmad NS, Islahudin F, Paraidathathu T. Factors associated with good glycaemic control among patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5(5):563–9.
[43] Contreras-Vergara A, Sifuentes-Franco S, Haack S, Graciano-Machuca O, Rodriguez-Carrizalez AD, López-Contreras AK, et al. Impact of Pharmaceutical Education on Medication Adherence and Its Clinical Efficacy in Patients with Type 2 Diabetes and Systemic Arterial Hypertension. Patient Prefer Adherence. 2022 Aug 5; 16:1999–2007.
[44] Scheurer D, Choudhry N, All V. Association Between Different Types of Social Support and Medication Adherence [Internet]. 2012. Available from: https://www.ajmc.com/view/association-between-different-types-of-social-support-and-medication-adherence
[45] Teng CL, Chan CW, Wong PS. Medication Adherence of Persons with Type 2 Diabetes in Malaysia: A Scoping Review and Meta-Analysis. Vol. 37, Journal of the ASEAN Federation of Endocrine Societies. ASEAN Federation of Endocrine Societies; 2022. p. 75–82.
[46] Beh YS, Gopalsamy K, Lee SLF, Vengadasalam VPP. Impact of Diabetes Medication Therapy Adherence Clinic (DMTAC) appointment intervals on glycaemic control in public health clinics across Perak, Malaysia. Malaysian Family Physician. 2022 Nov 30;17(3):105–13.
[47] Chai A, Ting SA. The effectiveness of diabetes medication therapy adherence clinic to improve glycaemic control among patients with type 2 diabetes mellitus: a randomised controlled trial [Internet]. Available from: www.random.org
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution 4.0 International License.
JBCS Publication Ethics
JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.
Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.
Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.
This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.
Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.
Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.
In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).
Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.
CONFLICT OF INTEREST
Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.
Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.
HUMAN AND ANIMAL RIGHTS
All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.
Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.
Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.
A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.
INFORMED CONSENT
For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.
DATA SHARING POLICY
JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible
Authors who do not wish to share their data must state that data will not be shared, and give the reason.
COPYRIGHT NOTICE
The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.
While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
